Article Information
History
- February 25, 2022.
Article Versions
- Version 1 (April 12, 2021 - 13:36).
- Version 2 (August 13, 2021 - 22:31).
- Version 3 (August 20, 2021 - 08:38).
- You are viewing Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Steven A. Kemp1,*,†,
- Oscar J. Charles2,†,
- Anne Derache3,
- Werner Smidt3,
- Darren P. Martin4,
- the ANRS 12249 TasP Study Group,
- Deenan Pillay2,
- Richard A. Goldstein2 and
- Ravindra K. Gupta2,3,*
- 1Cambridge Institute of Therapeutic Immunology & Infectious Disease (CITIID), Cambridge, UK
- 2Division of Infection & Immunity, University College London, London, UK
- 3Africa Health Research Institute, Durban, South Africa
- 4Department of Integrative Biomedical Sciences, University of Cape Town, South Africa
- ↵*Address for correspondence: Steven A Kemp, Cambridge Institute for Therapeutic Immunology and Infectious Diseases, Jeffrey Cheah Biomedical Centre, Cambridge CB2 0AW, UK, sk2137{at}cam.ac.uk or Ravindra K Gupta, Cambridge Institute for Therapeutic Immunology and Infectious Diseases, Jeffrey Cheah Biomedical Centre, Cambridge CB2 0AW, UK, Rkg20{at}cam.ac.uk
↵† Authors contributed equally
Posted February 25, 2022.
